Skip to main content
. 2018 Aug 29;13:4869–4880. doi: 10.2147/IJN.S166769

Figure 2.

Figure 2

The effect of GEM-HSA-NP on cell cycle arrest.

Notes: (A) The proportions of cell cycle analyzed by flow cytometry after BxPC-3 cells were treated with 0.05 μg/mL GEM, 0.1 μg/mL GEM-C14 and 2.083 μg/mL GEM-HSA-NP for 48 h, with or without 1 μM NBMPR. (B) Proportion of each phase of the cell cycle in each group of BxPC-3 cell line. (C) The proportions of cell cycle analyzed by flow cytometry after SW1990 cells were treated with 0.05 μg/mL GEM, 0.1 μg/mL GEM-C14 and 2.083 μg/mL GEM-HSA-NP for 48 h, with or without 1 μM NBMPR. (D) Proportion of each phase of the cell cycle in each group of SW1990 cell line.

Abbreviations: GEM, gemcitabine; GEM-C14, 4-N-myristoyl-gemcitabine; GEM-HSA-NP, gemcitabine-loaded human serum albumin nanoparticle; NBMPR, S-(4-nitrobenzyl)-6-thioinosine.